Price Alert

Novartis AG (NVS)

NYSE: NVS · Real-Time Price · USD

132.42

1.45 (1.11%)

At close: Oct 03, 2025, 3:59 PM

132.35

-0.05%

After-hours: Oct 03, 2025, 07:44 PM EDT

1.11% (1D)

Bid	132.21
Market Cap	256.35B
Revenue (ttm)	54.63B
Net Income (ttm)	9.62B
EPS (ttm)	6.86
PE Ratio (ttm)	19.3
Forward PE	14.13
Analyst	Hold
Dividends	$3.99

Ask	133
Volume	1,314,344
Avg. Volume (20D)	1,540,749
Open	132.24
Previous Close	130.97
Day's Range	131.91 - 133.38
52-Week Range	96.06 - 133.36
Beta	0.57
Ex-Dividend Date	Mar 12, 2025

About NVS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NVS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Novartis AG is scheduled to release its earnings on Oct 28, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 days ago

+2.71%

Shares of several drugmakers are trading higher af... Unlock content with Pro Subscription

4 days ago

+3.34%

Shares of several drugmakers are trading higher after President Trump announced a deal with Pfizer as well as the 'TrumpRx' site to decrease prices.

News

2 days ago · seekingalpha.com

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance

Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales ...

2 days ago · zacks.com

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

5 days ago · reuters.com

US FDA approves Novartis' drug for skin disease

The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.

6 days ago · wsj.com

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

The company is the latest pharma giant to move on price-cutting ahead of the Trump administration's deadline.

2 weeks ago · invezz.com

Novartis ramps up US stockpiles to shield against potential tariffs

Novartis AG (NOVN.S) has significantly increased its stockpiles of pharmaceuticals in the United States and is positioning itself to withstand potential tariffs, Chief Executive Officer Vas Narasimhan...

2 weeks ago · reuters.com

Novartis has stockpiles to withstand potential Trump tariffs, CEO says

Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interv...

2 weeks ago · zacks.com

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.